TY - CHAP
T1 - Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with 177Lu-and 90Y-DOTATOC (Tandem PRRNT) in a patient with a metastatic neuroendocrine tumor
AU - Todorović-Tirnanić, Mila
AU - Kaemmerer, Daniel
AU - Prasad, Vikas
AU - Hommann, Merten
AU - Baum, Richard P.
PY - 2013
Y1 - 2013
N2 - Aim: The aim of this chapter is to present the results of the first intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy (PRRNT) with 90Y- and 177Lu-DOTATOC using a handheld gamma probe and comparison with the findings of preoperative 68Ga-DOTATOC PET/CT in a patient with a metastatic neuroendocrine tumor (NET) of the ileum. Materials and Methods: A 56-year-old female patient, treated twice by PRRNT, was admitted for the third cycle and subsequent surgery. Before operation, the following studies were performed for restaging after the second cycle of PRRNT: 99mTc-MAG3 + TER, 99mTc-DTPA + GFR, abdominal ultrasonography, MRI of the abdomen, 68Ga-DOTATOC PET/CT as well as 18F-fluoride PET/CT. Serum tumor markers were measured before and after PRRNT. Tandem PRRNT was performed using 3000 MBq 90Y-DOTATOC and 6000 MBq 177Lu-DOTATOC. Whole-body scintigrams were obtained at 23 and 43 h. Five days after PRRNT, the patient was operated using a handheld gamma probe. Immunohistochemistry and histopathology of the resected tissue were performed. Results: Tandem PRRNT was very well tolerated by the patient. Before PRRNT, 68Ga-DOTATOC PET/CT revealed the primary tumor in the ileocoecal region as well as bilobular liver metastases and a right iliac bone lesion (osteoblastic on 18F-fluoride PET/CT). Compared with the previous findings, there was good therapy response (partial remission of the tumor lesions). No nephrotoxicity was observed. Serum chromogranin A (836 μg/l, n < 100) and serotonin (852 μg/l, n < 200) were strongly elevated. Posttherapy scans showed intense uptake in metastases and the primary tumor. Intraoperative gamma probe detectedin addition to the known lesionsbilateral ovarian metastases not visualized by 68Ga- DOTATOC PET/CT. Bilateral adnexectomy, right hemicolectomy, excision of hepatic metastases in S3, and partial resection of peritoneum were performed. Histopathology confirmed metastases in both ovaries. Conclusions: Gamma probe-guided surgery after 177Lu PRRNT is feasible and appears to be more sensitive than 68Ga-DOTATOC PET/CT. This technique might aid the surgeon in achieving more complete tumor resection through intraoperative detection of very small lesions (<5 mm) directly after PRRNT.
AB - Aim: The aim of this chapter is to present the results of the first intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy (PRRNT) with 90Y- and 177Lu-DOTATOC using a handheld gamma probe and comparison with the findings of preoperative 68Ga-DOTATOC PET/CT in a patient with a metastatic neuroendocrine tumor (NET) of the ileum. Materials and Methods: A 56-year-old female patient, treated twice by PRRNT, was admitted for the third cycle and subsequent surgery. Before operation, the following studies were performed for restaging after the second cycle of PRRNT: 99mTc-MAG3 + TER, 99mTc-DTPA + GFR, abdominal ultrasonography, MRI of the abdomen, 68Ga-DOTATOC PET/CT as well as 18F-fluoride PET/CT. Serum tumor markers were measured before and after PRRNT. Tandem PRRNT was performed using 3000 MBq 90Y-DOTATOC and 6000 MBq 177Lu-DOTATOC. Whole-body scintigrams were obtained at 23 and 43 h. Five days after PRRNT, the patient was operated using a handheld gamma probe. Immunohistochemistry and histopathology of the resected tissue were performed. Results: Tandem PRRNT was very well tolerated by the patient. Before PRRNT, 68Ga-DOTATOC PET/CT revealed the primary tumor in the ileocoecal region as well as bilobular liver metastases and a right iliac bone lesion (osteoblastic on 18F-fluoride PET/CT). Compared with the previous findings, there was good therapy response (partial remission of the tumor lesions). No nephrotoxicity was observed. Serum chromogranin A (836 μg/l, n < 100) and serotonin (852 μg/l, n < 200) were strongly elevated. Posttherapy scans showed intense uptake in metastases and the primary tumor. Intraoperative gamma probe detectedin addition to the known lesionsbilateral ovarian metastases not visualized by 68Ga- DOTATOC PET/CT. Bilateral adnexectomy, right hemicolectomy, excision of hepatic metastases in S3, and partial resection of peritoneum were performed. Histopathology confirmed metastases in both ovaries. Conclusions: Gamma probe-guided surgery after 177Lu PRRNT is feasible and appears to be more sensitive than 68Ga-DOTATOC PET/CT. This technique might aid the surgeon in achieving more complete tumor resection through intraoperative detection of very small lesions (<5 mm) directly after PRRNT.
KW - Intraoperative gamma probe detection
KW - Molecular imaging
KW - Neuroendocrine tumor
KW - Peptide receptor radionuclide therapy (PRRNT)
UR - http://www.scopus.com/inward/record.url?scp=84867045641&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-27994-2_28
DO - 10.1007/978-3-642-27994-2_28
M3 - Chapter
C2 - 22918778
AN - SCOPUS:84867045641
SN - 9783642279935
T3 - Recent Results in Cancer Research
SP - 487
EP - 496
BT - Theranostics, Gallium-68, and Other Radionuclides
PB - Springer Science and Business Media, LLC
ER -